What Omixon does

Omixon (legal entity Omixon Biocomputing Ltd.) is a Budapest, Hungary-headquartered molecular diagnostics company founded in 2011 that develops NGS-based products for HLA genotyping in transplant diagnostics. Its core technology stack spans two sequencing platforms: Holotype HLA, an 11-locus amplification assay paired with HLA Twin dual-algorithm software that runs on Illumina sequencers (MiniSeq, MiSeq, iSeq, NextSeq), and NanoTYPE, an 11-locus multiplex kit running on Oxford Nanopore MinION and GridION devices that delivers high-resolution HLA typing in under 5 hours — the first CE-IVDR certified HLA kit on the Nanopore platform. The product portfolio also includes HoloGRAFT, a donor-derived cell-free DNA (dd-cfDNA) assay for non-invasive post-transplant graft monitoring, plus a layer of professional services delivered through the ABHI-accredited Omixon Academy training program.

The company monetizes primarily through sale of reagent assay kits (Holotype, NanoTYPE, NanoTYPE MONO, HoloGRAFT ONE) sold in 24- and 96-test configurations to histocompatibility and immunogenetics (H&I) laboratories, solid organ and bone marrow transplant centers, and research institutions across 25+ countries. Software (HLA Twin, NanoTYPER) is bundled with assay kits on a recurring basis, and the Omixon Academy generates professional-services revenue from on-site training, validation support, and accreditation consulting. Distribution is hybrid: direct enterprise sales from Budapest and a Boston branch, complemented by a global network of regional distributors and agents. Omixon was acquired by Spain-based Werfen in May 2024 for approximately US$25 million in cash, and now operates as part of Werfen's Specialized Diagnostics transplant portfolio.

Name

Omixon

Legal name

Omixon Biocomputing Ltd.

Website

https://omixon.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

11–50 employees

Short description

Omixon is a Budapest-based molecular diagnostics company developing NGS-based HLA genotyping kits (Holotype HLA on Illumina, NanoTYPE on Oxford Nanopore) and donor-derived cfDNA monitoring assays (HoloGRAFT) for histocompatibility labs and transplant centers worldwide.

Ownership category

akta.pro rank

Product category

Transplant Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• HLA genotyping kits
• Transplant diagnostics
• Next generation sequencing
• Molecular diagnostics software
• Post-transplant monitoring

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. HLA Genotyping Reagents and Kits: Sale of NGS assay kits (Holotype HLA, NanoTYPE, NanoTYPE MONO) for HLA genotyping on Illumina and Oxford Nanopore platforms. Products sold in various configurations (5, 7, 11 loci) and formats (24 or 96 tests per kit). Both RUO (Research Use Only) and CE-IVD/CE-IVDR versions available.
2. Analysis Software Licensing: HLA Twin and NanoTYPER software products used for data analysis. Software provides automated genotyping with dual-algorithm validation. Offered as part of integrated product bundles with assay kits.
3. HoloGRAFT / HoloGRAFT ONE dd-cfDNA Assays: Donor-derived cell-free DNA monitoring assays for post-transplant surveillance. Sold as screening plates, monitoring assays, and software. Available as RUO products. New HoloGRAFT ONE formulation in single-use dry reagent format.
4. Training and Field Support Services: Omixon Academy provides ABHI-accredited training including onsite lab training (5, 3, or 1 day programs), webinars, workshops, software training, and validation support for ASHI and EFI accreditation. Provides Continued Education Credits (CECs).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Omixon develops and sells Next Generation Sequencing (NGS) based HLA genotyping assay kits (Holotype HLA, NanoTYPE, HoloGRAFT) paired with proprietary analysis software (HLA Twin, NanoTYPER) for histocompatibility and immunogenetics laboratories performing transplant matching. Products are sold in both Research Use Only (RUO) and CE-IVD/CE-IVDR certified versions, covering 5 to 11 HLA loci on Illumina and Oxford Nanopore sequencing platforms. The portfolio supports donor-recipient matching for bone marrow, stem cell, and solid organ transplantation as well as non-invasive post-transplant monitoring via dd-cfDNA testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Holotype HLA Combination NGS Assay and Software product for high-resolution HLA genotyping on Illumina sequencers. Covers 5, 7, or 11 HLA loci. Combines amplification reagents and HLA Twin software for fully automated end-to-end workflow. Available in CE-IVD versions for Europe. For histocompatibility and immunogenetics laboratories performing donor-recipient matching for transplantation.
• HLA Twin Software Dual-algorithm genotyping software with two orthogonal algorithms for double validation and 24 locus-level quality control metrics. Features the proprietary Traffic Light System that swiftly guides analysts through interpretation of results. For HLA genotyping analysis on data generated from Holotype HLA or other sequencing workflows.
• NanoTYPE Multiplex 11-locus HLA amplification kit compatible with Oxford Nanopore MinION and GridION sequencing platforms. Delivers high-resolution HLA typing in under 5 hours turnaround time. First CE-IVDR certified HLA kit based on Oxford Nanopore Technologies. For clinical histocompatibility labs requiring rapid HLA typing for deceased donor matching.
• NanoTYPE MONO & MONOall Single-locus HLA testing kits for high-resolution analysis using nanopore technology. Available in 24 and 96 formats as RUO products. Enables sample confirmation, repetition, and evaluation of genetic markers for individual HLA loci.
• NanoTYPE HLA-11 Plus Full-gene HLA genotyping kit covering all 11 classical loci from 5'UTR to 3'UTR using nanopore sequencing. Designed for comprehensive coverage and future-ready HLA typing on MinION and GridION platforms.
• HoloGRAFT ONE Donor-derived cell-free DNA (dd-cfDNA) assay in a single-use dry reagent strip-of-12-tube format for post-transplant monitoring. Uses copy number variant markers absent in patient genotype by design and measures absolute concentration of donor-derived cfDNA. For transplant programs and labs performing non-invasive graft rejection detection.
• Omixon Academy Training ABHI-accredited training and education services for HLA laboratories including onsite lab training (5, 3, or 1 day programs), webinars, workshops, online demos, software training, validation support, and Continued Education Credits. Includes hands-on training and complex case datasets. For clinical labs adopting Omixon's NGS-based HLA genotyping products.

Quantifiable outcome

• 29% of bone marrow transplant patients saw survival probability increase from 30% to 54% following introduction of the Holotype test (retrospective studies)
• +6 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability2 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Oxford Nanopore TechnologiescoreTechnology or Integration · 11 June 2024Non-exclusive agreement allowing NanoTYPER software to process data without the previous 48-hour restriction, enabling commercial delivery of high-resolution HLA typing results within 4-5 hours after sample receipt. NanoTYPE is the first HLA genotyping kit based on Oxford Nanopore Technologies to receive CE-IVDR certification. Omixon uses MinION and GridION platforms, with validation ongoing for PromethION 2 Solo and integrated P2 for processing up to 96 samples on one flow cell.
• PIRCHEcoreStrategic or Co-development PartnerOmixon is a Preferred Partner of PIRCHE. The PIRCHE Web Service provides epitope matching tools integrated into HLA Twin software, enabling automated transfer of HLA allele data without manual entry. Omixon customers receive free access to PIRCHE's full range of epitope matching modules.
• The Children's Hospital of Philadelphia (CHOP)coreTechnology or IntegrationHolotype HLA assay was invented and designed at CHOP by Professor Dimitri Monos. Omixon licensed the technology from CHOP. CHOP has typed over 3,000 patient samples in clinical routine and serves as a reference lab for product demonstrations.
• Semmelweis University Transplants Clinic and Városmajori SzívklinikaminorStrategic or Co-development PartnerResearch collaboration with Semmelweis University Transplants Clinic and Városmajori Szívklinika (Heart Clinic) for the development of HoloGRAFT transplant monitoring test. Collaboration focused on non-invasive post-transplant monitoring using blood tests instead of needle biopsies.
• St Louis Hospital, AP-HP ParisminorChannel Partner/ Reseller/ DistributorSupply agreement in place with St Louis Hospital (AP-HP, Paris) for NanoTYPE product. Hospital participates in urgent transplant HLA typing alongside standard of care testing.
• International Immunogenetics Information System (IMGT/HLA)minorOthersOmixon is a continuous sponsor of the IMGT/HLA database, the primary reference database for HLA alleles. Sponsorship provides mutual benefit as Omixon experts rely on the HLA allele database for product development and validation.
• Hungarian Academy of Sciences (MTA) - Nephrology Research GroupminorStrategic or Co-development PartnerConsortium partner in the 2017-1.3.1-VKE-2017-00006 project focused on developing treatments for improving kidney transplant outcomes. The MTA research group (operating at Semmelweis University) focused on kidney damage and transplant pathophysiology, developing new therapeutic approaches and optimized transplant storage solutions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CareDx: CareDx is the leader in donor-derived cell-free DNA (AlloSure) testing for transplant monitoring and offers AlloSeq HCT for HLA typing. It is the most direct peer to Omixon's HoloGRAFT dd-cfDNA assay and competes for the same transplant center customers.
• One Lambda (Thermo Fisher Scientific): One Lambda is the long-standing market leader in HLA typing reagents and software, acquired by Thermo Fisher Scientific. It is the most direct competitor to Omixon's Holotype HLA and HLA Twin products, serving the same H&I laboratory customers with sequencing-based and legacy HLA typing assays.
• GenDx: GenDx is a Dutch specialty diagnostics company offering NGS-based HLA typing reagents (NGmix, AlleleSEQR) and analysis software (SBTengine, NGSengine). It is a direct competitor to Omixon's Holotype HLA in transplant laboratories worldwide.
• Natera: Natera is a public molecular diagnostics company offering Prospera, a donor-derived cell-free DNA test for transplant monitoring, alongside its broader reproductive and oncology cfDNA franchises. It directly competes with Omixon's HoloGRAFT in dd-cfDNA transplant surveillance.
• Eurofins Genomics: Eurofins Genomics is a major global provider of genomic services including HLA typing, NGS reagents, and Sanger-based HLA testing. Omixon's Senior R&D Director Elmar Schilling was previously head of NGS Manual Innovation at Eurofins Genomics, evidencing the direct personnel and product overlap.
• TBG Diagnostics: TBG Diagnostics offers HLA typing kits and laboratory automation (DX-A Robot) for transplant diagnostics, with Asian market strength. It directly competes with Omixon in the HLA reagent space, including automated workflows on which Holotype HLA is also validated.
• HistoGenetics: HistoGenetics is an HLA typing reference laboratory providing high-resolution sequencing-based HLA typing services and reagents. It directly competes with Omixon in serving bone marrow registries and transplant centers needing HLA genotyping.
• Linkage Biosciences: Linkage Biosciences develops HLA typing software (LinkSeq) and reagents for transplant diagnostics. It competes directly with Omixon's HLA Twin software and Holotype HLA workflow in H&I laboratories.

Broad incumbents

• Immucor: Immucor is a Werfen-owned (acquired 2023) transfusion and transplant diagnostics company. As Omixon's corporate sibling under Werfen's SpecializedDiagnostics portfolio, it is a complementary peer in transplant diagnostics with broader product reach.
• Bio-Rad Laboratories: Bio-Rad is a broad life sciences and clinical diagnostics company with an established HLA typing product line (e.g., SSO and SSP-based kits). It is a broad incumbent competing across multiple HLA methods with overlapping customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC1aBFG8dV2GW9KK7GZ2HMyQ
• Xx.com/OmixonBio
• Facebookfacebook.com/1406
• LinkedInlinkedin.com/company/omixon

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omixon